Market Introduction
Chronic cough is defined as a persistent cough that lasts long up to 6-8 weeks. It significantly affects the patients' lives by interrupting sleeping, vomiting, light-headedness, and even rib fractures. It is caused due to multiple reasons such as infections, asthma, gastroesophageal reflux disease (GERD), among others.
Market Overview and Dynamics
The North America Chronic Cough market is projected to reach US$ 3,944.89 million by 2027 from US$ 2,118.42 million in 2019; it is estimated to grow with a CAGR of 8.1% from 2020 to 2027. The growth of the North America chronic cough market is attributed to the rising incidences of chronic cough, growing product developments to treat chronic cough. However, product recalls limits the growth of market in this region. Countries in Asia Pacific are expecting to witness huge challenge due to growing COVID-19. Due to outbreak of disease, healthcare industries has been affected badly. Due to growing coronavirus cases, many business related activities such as product launches and product promotion conferences has been postponed, leading to restraining the growth of the market.
Key Market Segments
Based on drug class, the North America Chronic Cough market is segmented into antihistamines, corticosteroids, decongestants, combination drug, antibiotics, acid blockers, and other drug class. In 2019, the combination drug segment held a larger share of the market. And is expected to grow at a faster rate during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to while preparing the North America Chronic Cough Market report are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.
Novartis AG, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc., Bayer AG, Mylan N.V., Amneal Pharmaceuticals, Inc., Cipla Inc., Reckitt Benckiser Group plc., Sun Pharmaceutical Industries Ltd, and Aurobindo Pharma Ltd.
Reasons to buy the report
NORTH AMRICA CHRONIC COUGH MARKET SEGMENTATION
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 2,118.42 Million |
| Market Size by 2027 | US$ 3,944.89 Million |
| CAGR (2020 - 2027) | 8.1% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Chronic Cough Market is valued at US$ 2,118.42 Million in 2019, it is projected to reach US$ 3,944.89 Million by 2027.
As per our report North America Chronic Cough Market, the market size is valued at US$ 2,118.42 Million in 2019, projecting it to reach US$ 3,944.89 Million by 2027. This translates to a CAGR of approximately 8.1% during the forecast period.
The North America Chronic Cough Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Chronic Cough Market report:
The North America Chronic Cough Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Chronic Cough Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Chronic Cough Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Chronic Cough Market
